Cambridge-based Nimbus Therapeutics, which has raised $67 million in venture funding, has nabbed another $200 million from its big-name partner Gilead Sciences for its drug to treat non-alcoholic steatohepatitis.
The company, founded at Atlas Venture in 2009, relies on computational chemistry to a greater degree than other biotechs. In fact, the company says that the drug that Gilead (Nasdaq: GILD) acquired last year for $400 up front and another $800 million in potential milestones, is the first…
Cambridge-based Nimbus Therapeutics, which has raised $67 million in venture funding, has nabbed another $200 million from its big-name partner Gilead Sciences for its drug to treat non-alcoholic steatohepatitis.
The company, founded at Atlas Venture in 2009, relies on computational chemistry to a greater degree than other biotechs. In fact, the company says that the drug that Gilead (Nasdaq: GILD) acquired last year for $400 up front and another $800 million in potential milestones, is the first…